{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aptorum Group Limited"},"Symbol":{"label":"Symbol","value":"APM"},"Address":{"label":"Address","value":"17 HANOVER SQUARE 17TH FLOOR, GUANGDONG INVESTMENT TOWER, LONDON, W1S 1BN, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2080929299"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services."},"CompanyUrl":{"label":"Company Url","value":"https://www.aptorumgroup.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Clark Cheng","title":"Executive Director &amp; Chief Medical Officer"},{"name":"Wai-Yip Lee","title":"Head-Research &amp; Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}